1.
Melgaard L, Gorst-Rasmussen A, Søgaard P, Rasmussen LH, Lip GYH, Larsen TB. Diabetes
mellitus and risk of ischemic stroke in patients with heart failure and no atrial
fibrillation. Int J Cardiol [Internet]. 2016;209:1–6. Available from: http://dx.doi.org/10.1016/j.ijcard.2016.02.004
2.
Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard B V., et al. AHA Scientific
Statement: Diabetes and Cardiovascular Disease. American Heart Association Scientific
Statement. 1999.
3.
American Diabetes Association. Cardiovascular disease and risk management: Standards
of medical care in Diabetesd2018. Diabetes Care. 2018;41(January): S86–104.
4.
World Health Organization. Cardiovascular diseases: Key facts [Internet]. 2017. Available
from: http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(CVD)
5.
Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park J-G, et al. Polyvascular
disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the
IMPROVE-IT trial. lancet Diabetes Endocrinol. 2018 Nov;
6.
Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid
trial: What we learn from subgroup analyses. Diabetes Care. 2011;34(SUPPL. 2):107–8.
7.
Pascale M, Murray N, Bachmann M, Barton G, Clark A, Howe A, et al. Study Protocol:
The Norfolk Diabetes Prevention Study [NDPS]: a 46 month multi - centre, randomised,
controlled parallel group trial of a lifestyle intervention [with or without additional
support from lay lifestyle mentors with Type 2 diabetes] to prevent. BMC Public Health
[Internet]. 2017;17(1):1–21. Available from: http://dx.doi.org/10.1186/s12889-016-3929-5
9.
World Health Organization. Global report on diabetes. [Internet]. Vol. 58, World Health
Organization. 2016. Available from: http://www.who.int/about/licensing/ copyright_form/index.html).%0AThe
10.
Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA.
1979 May;241(19):2035–8.
11.
Chen R, Ovbiagele B, Feng W. Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals
and Outcomes. Am J Med Sci [Internet]. 2016 Apr;351(4):380–6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27079344
13.
Kang YM, Cho YK, Lee SE, Park JY, Lee WJ, Kim YJ, et al. Cardiovascular diseases and
life expectancy in adults with type 2 diabetes: A Korean national sample cohort study.
J Clin Endocrinol Metab. 2017;102(9):3443–51.
14.
Gerstein HC, Miller ME, Bigger JT, Buse JB, Cushman WC, Genuth S, et al. Effects of
Intensive Glucose Lowering in Type 2 Diabetes: The ACCORD study group. N Engl J Med.
2008;358(24):563–74.
15.
Barer Y, Cohen O, Cukierman-Yaffe T. The effect of glycemic control on cardiovascular
disease in individuals with type 2 diabetes with pre-existing cardiovascular disease
- a systematic review and meta-analysis. Diabetes, Obes Metab [Internet]. 2018;(November):1–4.
Available from: http://doi.wiley.com/10.1111/dom.13581
16.
King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical
and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999 Nov;48(5):643–8.
17.
Liu X, Wang L, Wang P, Liu R, Yang K, Qian X, et al. The Dynamics of Type 2 Diabetes
Mellitus Prevalence and Management Rates among Rural Population in Henan Province,
China. J Diabetes Res. 2017;2017:9092759.
18.
World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus
and its Complications. 1999.
19.
International Diabetes Federation. IDF Diabetes Atlas. 2017.
20.
International Diabetes Federation. Suvi Karuranga, Joao da Rocha Fernandes, Yadi Huang
BM (Editors). IDF Diabetes Atlas - Eigth Edition [Internet]. 2017. Available from:
www.diabetesatlas.org
21.
Kautzky-willer A, Harreiter J, Pacini G. Sex, and Gender Differences in Risk, Pathophysiology,
and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2018;37(3):278–316.
22.
Mosca L, Barrett-Connor E, Kass Wenger N. Sex/gender differences in cardiovascular
disease prevention: What a difference a decade makes. Circulation. 2011;124(19):2145–54.
23.
Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, et al. Sex difference
in stroke: epidemiology, clinical presentation, medical care, and outcomes. Natl Institutes
Heal. 2009;7(10):915–26.
24.
Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between
insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol
[Internet]. 2018;17(1):1–14. Available from: https://doi.org/10.1186/s12933-018-0762-4
25.
Patel A, MacMahon S, Chalmers J, Neal B. Intensive blood glucose control and vascular
outcomes in patients with type 2 diabetes. N Engl J Med [Internet]. 2008;358(24):2560–72.
Available from: http://repository.ubn.ru.nl/handle/2066/69678
26.
Munoz-Rivas N, Mendez-Bailon M, Hernandez-Barrera V, de Miguel-Yanes JM, Jimenez-Garcia
R, Esteban-Hernandez J, et al. Type 2 Diabetes and Hemorrhagic Stroke: A Population-Based
Study in Spain from 2003 to 2012. J Stroke Cerebrovasc Dis. 2016 Jun;25(6):1431–43.
27.
Aambo A, Klemsdal TO. Cardiovascular disease and diabetes in patients with African
or Asian background. Aambo, Arlid. 2017;137(22).
29.
Wang Z, Wang X, Hao G, Chen Z, Zhang L, Shao L, et al. A national study of the prevalence
and risk factors associated with peripheral arterial disease from China: The China
Hypertension Survey, 2012-2015. Int J Cardiol. 2018 Oct;
30.
Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic
nephropathy after pancreas transplantation. N Engl J Med. 1998 Jul;339(2):69–75.